EUCTR2020-001074-30-NL进行中（未招募）1 期
eo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial
etherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL)0 个研究点目标入组 40 人开始时间: 2020年5月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 years or older.
- •2. Patient is able to understand and comply with the protocol requirements and has signed the informed consent form.
- •3. World Health Organization (WHO) Performance Status 0 or 1 (Appendix B).
- •4. Patients with histologically or cytologically confirmed, primary or recurrent stage III-IVA CSCC of all body sites.
- •Primary tumor sites Head and Neck:
- •oVermillion border lip: C00.0, C00.1, C00.2
- •oSkin of lip NOS: C44.0
- •oExternal ear: C44.2
- •oSkin face unspecified (ao: external lip and nasal vestibulum): C44.3
- •oSkin scalp and neck: C44.4
- •oOverlapping lesion of skin: C44.8
- •oPrimary site eyelid: C44.1
- •CSCC outside head and neck area, but not vulva, anus and penis
- •Patients with histologically or cytologically proven stage I-II CSCC, only in the case of:
- •Presence of multifocal disease for which extensive and/or mutilating surgery is necessary (e.g. near-total scalp resection).
- •Situated in an anatomical localization that necessitates extensive and/or mutilating surgery (e.g. orbital exenteration).
- •5. Eligible for standard-of-care, curatively intended surgery with or without adjuvant radiotherapy.
- •6. Screening laboratory values must meet the following criteria: WBC = 2.0x109 /L, Neutrophils =1.5x109 /L, Platelets =100 x109 /L, Hemoglobin =5.5 mmol/L, Creatinine =1.5x ULN, AST = 1.5 x ULN, ALT = 1.5 x ULN, Bilirubin =1.5 X ULN (except subjects with Gilbert Syndrome, who are eligible when total bilirubin < 3.0 mg/dL).
- •7. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. They should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of the investigational drug.
- •8. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) prior to the start of nivolumab or nivolumab + ipilimumab.
- •9. Men who are sexually active with WOCBP must use a contraceptive method with a failure rate of less than 1% per year and will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Surgically sterile or azoospermic men do not require aforementioned contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •4.3Exclusion criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1. Distantly metastasized (stadium IVb) CSCC.
- •2. SCC localized in a mucosal surface (i.e. anus, vulva, penis or mucosal portion of lip).
- •3. Patients for whom SOC consists of definitive (brachy)radiotherapy.
- •4. Primary or recurrent CSCC appearing in an area that has been previously irradiated.
- •5. Prior anti-CTLA4 or anti-PD1 immunotherapy.
- •6. Active human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •7. A positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C antibody (HCV Ab).
- •8. Subjects with any active autoimmune disease or a documented history of autoimmune disease, except for:
- •Subjects with vitiligo
- •Resolved childhood asthma/atopy
- •Residual hypothyroidism due to an autoimmune condition requiring only hormone replacement
- •Psoriasis not requiring systemic treatment
- •Any condition not expected to recur in the absence of an external trigger.
- •9. Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or AE.
- •10. A concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- •11. Pregnant or nursing.
- •12. A history of allergy to study drug components and/or a history of severe hypersensitivity to any monoclonal antibody.
- •13. Use of other investigational drugs 30 days before study drug administration and 5 half times before study inclusion.
- •14. Use of prohibited medication at start of study period.
研究者
相似试验
招募中
2 期
eo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trialNL-OMON52693Antoni van Leeuwenhoek Ziekenhuis40
进行中（未招募）
1 期
Ipilimumab in combination with Nivolumab followed by Nivolumab monotherapy in patients with unresectable or oligometastatic melanoma.Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2018-002172-40-ITISTITUTO EUROPEO DI ONCOLOGIA35
进行中（未招募）
1 期
EOpredict-Lung is a clinical study in subjects with histologically or cytologically confirmed, early stage or locally advanced non-small cell lung cancer (NSCLC) eligible for curative resection. This study will determine the feasibility of two cycles of preoperative immunotherapy with nivolumab or as combination nivolumab plus relatlimab.non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002478-29-DEniversity Hospital Essen60
招募中
2 期
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)2024-513074-22-00Universitaetsklinikum Essen AöR, Universitaetsklinikum Essen AöR90
进行中（未招募）
1 期
EOpredict-Lung is a clinical study in subjects with histologically or cytologically confirmed, early stage or locally advanced non-small cell lung cancer (NSCLC) eligible for curative resection. This study will determine the feasibility of two cycles of preoperative immunotherapy with nivolumab or as combination nivolumab plus relatlimab.non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002478-29-BEniversity Hospital Essen60